Meridian Bioscience (Meridian Bioscience) Cash-to-Debt : 2.63 (As of Sep. 2022)

View and export this data going back to 1986. Start your Free Trial

What is Meridian Bioscience Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Meridian Bioscience's cash to debt ratio for the quarter that ended in Sep. 2022 was 2.63.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Meridian Bioscience could pay off its debt using the cash in hand for the quarter that ended in Sep. 2022.

The historical rank and industry rank for Meridian Bioscience's Cash-to-Debt or its related term are showing as below:

VIVO's Cash-to-Debt is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 1.35
* Ranked among companies with meaningful Cash-to-Debt only.

Meridian Bioscience Cash-to-Debt Historical Data

The historical data trend for Meridian Bioscience's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Meridian Bioscience Cash-to-Debt Chart

Meridian Bioscience Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Cash-to-Debt

Get a 7-Day Free Trial

1.19

0.82

0.71

0.76

2.63

Meridian Bioscience Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash-to-Debt	Get a 7-Day Free Trial															0.76	1.31	2.34	2.63	2.63

Competitive Comparison of Meridian Bioscience's Cash-to-Debt

For the Diagnostics & Research subindustry, Meridian Bioscience's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Meridian Bioscience's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Meridian Bioscience's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Meridian Bioscience's Cash-to-Debt falls into.

Meridian Bioscience Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Meridian Bioscience's Cash to Debt Ratio for the fiscal year that ended in Sep. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	81.453	/	(1.83	+	29.127)
	=	2.63

Meridian Bioscience's Cash to Debt Ratio for the quarter that ended in Sep. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	81.453	/	(1.83	+	29.127)
	=	2.63

Meridian Bioscience (NAS:VIVO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Meridian Bioscience Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Meridian Bioscience (Meridian Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (NAS:VIVO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3471 River Hills Drive, Cincinnati, OH, USA, 45244

Website

https://www.meridianbioscience.com

Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.

Executives

Julie Diana Smith	officer: Sr VP, Controller, PAO	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John P. Kenny	director, officer: Chief Executive Officer	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Andrew S. Kitzmiller	officer: EVP & CFO	ONE BATESVILLE BLVD., BATESVILLE IN 47006
Bryan T Baldasare	officer: Interim CFO & Chief Acctg Off	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Rice John Mccune Jr.	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Bihl Anthony P Iii	director	807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
Tony Serafini-lamanna	officer: Executive VP-Diagnostics	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Felicia Williams	director	C/O MACY'S, INC., 151 WEST 34TH STREET, NEW YORK NY 10001
John Mcilwraith	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
David Phillips	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
James M. Anderson	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Dwight E Ellingwood	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lawrence Baldini	officer: Exec VP, Operations & IS	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric S. Rasmussen	officer: EVP, Bus. Development/Strategy	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lourdes Weltzien	officer: EVP, Life Science	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244